为观察尼莫地平对创伤性蛛网膜下胜出血（t－SAH）的治疗作用，作者将45例患者随机分为常规治疗组（n＝22）和常规加尼莫地平治疗组（n＝23），所有患者均行颅内压（ICP）监护并按国际GOS预后评分标准进行疗效判定。结果预后不良者在常规治疗组中占59％，而在尼莫地平组仅占26％（P＜0．05），两组ICP变化则无显著性差异（P＞0．05）。研究结果显示，应用尼莫地平治疗t－SAN能明显降低死残率，改善预后，且对ICP无明显影响。 To observe the therapeutic effect of nimodipine on the treatment of traumatic subarachnoid hemorrhage (t-SAH), 45 patients were randomly divided into conventional treatment (n = 22) and conventional nimodipine (n = 23) ). All patients under ICP were monitored by ICP and the efficacy was assessed according to the international GOS prognostic score. Results Patients with poor prognosis accounted for 59% of those in the conventional treatment group and only 26% in the nimodipine group (P <0.05). There was no significant difference in ICP between the two groups (P> 0.05). The results show that the use of nimodipine in the treatment of t-SAN can significantly reduce the mortality rate and improve prognosis, and had no significant effect on ICP.